Innovative Medicines
Developing next generation medicines
that will lead the fight against cancer & inflammation.
that will lead the fight against cancer & inflammation.
Breaking News
Rhizen x Curon – Tenalisib Licensing Deal Press Release Statement.
OUR STORY
The Rhizen Journey!
Our Journey To Be A Leading Oncology-focused Specialty Company Developing Differentiated Products Through Cutting-edge Science and Strategic Partnerships Started in 2008.
0
+
TARGETS
Novel programs targeting multiple hallmarks of cancer
0
+
Trials
Assessing the safety and efficacy of our novel pipeline
0
+
PATENTS
Accumulated from dedicated research efforts for the last 12 years
Our Team
We Are All In To Make It Possible
Swaroop Vakkalanka, PhD
Founder & CEO
Proven and seasoned senior leadership team with expertise spanning the entire discovery-development-commercialization value chain
OUR PARTNERING STRATEGY
Flexible Global and Regional Approach
Progress in-house assets through clinical POC and out-license to global partners for large markets
In-license differentiated assets for development and commercialization
Build a pipeline of specialty assets across the oncology and onco-inflammation space
In-license differentiated assets for development and commercialization
Build a pipeline of specialty assets across the oncology and onco-inflammation space
pricing Plans
The Best Solutions for Our Clients
